Stelara
FDA expands Stelara indication to cover paediatric plaque psoriasis
July 31, 2020Medical Communications, Sales and Marketing Janssen, Stelara, pharma, plaque psoriasis
Janssen’s IL-12 and IL-23 inhibitor Stelara (ustekinumab) has had its approved indications expanded by the FDA to include the treatment …
NICE backtracks to approve Janssen’s Stelara in ulcerative colitis
April 28, 2020Manufacturing and Production, Research and Development Janssen, NICE, Stelara, ulcerative colitis
NICE has recommended Janssen’s Stelara (ustekinumab) for the treatment of moderately to severely active ulcerative colitis (UC), a move which …
Scottish Medicines Consortium approves new drugs in multiple sclerosis, ulcerative colitis and diabetes
April 15, 2020Research and Development, Sales and Marketing Biogen, Fambyra, Janssen, NHS, Rimzoic, Sandoz, Sanofi, Scotland, Scottish Medicines Consortium, Stelara, Suliqua, pharma
Medical regulation must still continue even in a global pandemic, and the Scottish Medicines Consortium, (SMC) has ploughed on with …
Janssen shows off Phase 3b interim data for Stelara in Crohn’s disease
February 18, 2020Manufacturing and Production, Research and Development Crohn’s disease, Janssen, Stelara, crohn's disease, pharma
Janssen has revealed new interim Phase 3b data from a study investigating the efficacy of Stelara (ustekinumab) in the treatment …
European Commission expands Stelara for paediatric moderate to severe plaque psoriasis
January 24, 2020Research and Development Europe, Janssen, Stelara, pharma
Janssen’s Stelara (ustekinumab) has seen its label expanded in Europe to include the treatment of moderate to severe plaque psoriasis …
UCB’s bimekizumab meets primary and secondary endpoints, beating Janssen’s Stelara in chronic plaque psoriasis
October 17, 2019Research and Development Stelara, UCB Pharma, bimekizumab, pharma, plaque psoriasis
UCB Pharma has announced new data from the first of three Phase 3 studies investigating the efficacy of its IL-17A …
Janssen’s Stelara becomes first European-approved biologic IL-12/IL-23 inhibitor for ulcerative colitis
September 5, 2019Sales and Marketing Europe, Janssen, Stelara, pharma, ulcerative colitis
Janssen has announced that its therapy Stelara (ustekinumab) hass secured a label expansion from the European Commission, approving the drug …
Janssen’s ulcerative colitis treatment shows positive results in phase 3 trials
March 13, 2019Manufacturing and Production, Research and Development Jansenn, Stelara, phase 3 trials, ulcerative colitis
Janssen’s ulcerative colitis treatment, Stelara (ustekinumab subcutaneous) has shown positive results as maintenance therapy in phase 3 trials. The study …
Novartis’ Cosentyx tops Janssen’s Stelara in moderate-to-severe psoriasis trial
March 5, 2019Manufacturing and Production, Research and Development Cosentyx, Janssen, Novartis, Stelara, pharma, psoriasis
New data has been revealed in support of Novartis’ Cosentyx (secukinumab) in the treatment of moderate-to-severe plaque psoriasis, demonstrating the …
J&J joins in on industry price hiking; almost 500 drug prices increased in 2019 so far
January 11, 2019Medical Communications, Sales and Marketing J&J, JJ, Stelara, US, Xarelto, Zytiga, pharma, price hikes
It’s only the second week of the New Year, and Johnson & Johnson has announced plans to hike the prices …
Janssen’s Stelara shows promise across two dosages in ulcerative colitis
October 9, 2018Manufacturing and Production, Research and Development Janssen, Stelara, pharma, ulcerative colitis
Janssen’s biologic therapy Stelara (ustekinumab) has shown new efficacy in the treatment of moderate to severe ulcerative colitis in two …
Novartis debuts new data showing Cosentyx’s superiority over Janssen’s Stelara in psoriasis
January 16, 2018Manufacturing and Production, Research and Development Cosentyx, Janssen, Novartis, Stelara, pharma
Novartis has lifted the curtain on new data comparing the efficacy of Cosentyx (secukinumab) to Janssen’s Stelara (ustekinumab) in achieving …
Janssen’s Stelara shows improvement in Crohn’s symptoms within one week, new findings reveal
October 30, 2017Manufacturing and Production, Research and Development Crohn’s disease, Janssen, Stelara, crohn's disease, pharma
Janssen has unveiled new data on Stelara (ustekinumab) in the treatment of patients with moderately to severely active Crohn’s disease …
FDA expands Janssen’s Stelara to cover adolescent psoriasis patients
October 16, 2017Sales and Marketing FDA, Janssen, Stelara, pharma, psoriasis
Janssen has announced that the FDA has approved an expanded indication for its psoriasis therapy Stelara (ustekinumab) for the treatment …
NICE recommends Janssen’s first-of-its-kind Crohn’s drug Stelara
May 3, 2017Research and Development, Sales and Marketing Crohn’s disease, Janssen, NICE, Stelara, crohn's disease
Janssen has announced that it has secured recommendation from NICE for Stelara (ustekinumab) in the indication of moderately to severely …
Latest content
